Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 13/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20190385 | 0.81 | MCHR1 (0.51) | KDM4ENPC1ALDH1A1RAB9ASCN5A | |
| SCHEMBL20208546 | 0.81 | SCN5A (0.61) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL20190544 | 0.80 | SCN5A (0.67) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL13336494 | 0.79 | NPC1 (0.51) | KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL19781540 | 0.78 | CYP1A2 (0.54) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL23087272 | 0.77 | DYRK1A (0.45) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL1542371 | 0.76 | CHEK1 (0.49) | KDM4ENPC1ALDH1A1RAB9A | |
| SCHEMBL21644144 | 0.76 | DYRK1A (0.59) | MAPTCYP1A2 | |
| SCHEMBL16304078 | 0.75 | KEAP1 (0.44) | KDM4ENPC1ALDH1A1GAAMAPT | |
| SCHEMBL20190641 | 0.75 | CYP1A2 (0.66) | KDM4ENPC1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098500-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188839-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | KDM4E 2066/4885NPC1 218/4885ALDH1A1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.